<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30083066</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1179-5549</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>12</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Clinical Medicine Insights. Oncology</Title>                <ISOAbbreviation>Clin Med Insights Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>Survival Study of Triple-Negative and Non-Triple-Negative Breast Cancer in a Brazilian Cohort.</ArticleTitle>            <Pagination>                <MedlinePgn>1179554918790563</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1179554918790563</ELocationID>            <Abstract>                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Brazilian cohort and identify potential prognostic factors.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">This hospital-based retrospective cohort study included 447 women with breast cancer treated at referral centers in Southeastern Brazil. Overall and disease-free survival were compared; prognostic factors were evaluated.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Triple-negative breast cancer corresponded to 19.5% of breast cancer diagnosis and was more prevalent among nonwhite and less educated women. The patients with TNBC tended to present with stage III cancer, high p53 expression, lymphocytic infiltration, and multifocality and treated with radical surgery and chemotherapy. The 5-year overall and disease-free survival were 62.1% and 57.5% for TNBC and 80.8% and 75.3% for non-TNBC, respectively (<i>P</i> &lt; .001). The TNBC recurrence was associated with multicentricity, whereas lymph node involvement increased the risk of both recurrence and death. Non-TNBC worse clinical course was associated with nonwhite ethnicity, lower education level, lymph node involvement, and advanced stage.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Triple-negative breast cancer exhibited a more aggressive behavior, earlier and more frequent recurrence, and worse survival compared with non-TNBC. While biological and social variables were associated with poorer prognosis in non-TNBC, only lymph node involvement and multicentricity were correlated with worse clinical outcomes in TNBC.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gonçalves</LastName>                    <ForeName>Homero</ForeName>                    <Initials>H</Initials>                    <Suffix>Jr</Suffix>                    <Identifier Source="ORCID">https://orcid.org/0000-0001-5960-1482</Identifier>                    <AffiliationInfo>                        <Affiliation>Instituto Oncológico de Juiz de Fora/Hospital 9 de Julho, Juiz de Fora, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Post-Graduate Program in Health, Faculty of Medicine, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guerra</LastName>                    <ForeName>Maximiliano Ribeiro</ForeName>                    <Initials>MR</Initials>                    <AffiliationInfo>                        <Affiliation>Post-Graduate Program in Public Health, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Inserm U900, Institut Curie, PSL Research University, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Duarte Cintra</LastName>                    <ForeName>Jane Rocha</ForeName>                    <Initials>JR</Initials>                    <AffiliationInfo>                        <Affiliation>Instituto Oncológico de Juiz de Fora/Hospital 9 de Julho, Juiz de Fora, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fayer</LastName>                    <ForeName>Vívian Assis</ForeName>                    <Initials>VA</Initials>                    <AffiliationInfo>                        <Affiliation>Post-Graduate Program in Public Health, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Brum</LastName>                    <ForeName>Igor Vilela</ForeName>                    <Initials>IV</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bustamante Teixeira</LastName>                    <ForeName>Maria Teresa</ForeName>                    <Initials>MT</Initials>                    <AffiliationInfo>                        <Affiliation>Post-Graduate Program in Health, Faculty of Medicine, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Post-Graduate Program in Public Health, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Med Insights Oncol</MedlineTA>            <NlmUniqueID>101525771</NlmUniqueID>            <ISSNLinking>1179-5549</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2016 Jan 01;7(2):167-73</RefSource>                <PMID Version="1">26819640</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2018 Jan;19(1):40-50</RefSource>                <PMID Version="1">29233559</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Womens Health (Larchmt). 2009 Jun;18(6):883-93</RefSource>                <PMID Version="1">19514831</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2011 Jul;121(7):2750-67</RefSource>                <PMID Version="1">21633166</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2011 Jul 1;29(19):2628-34</RefSource>                <PMID Version="1">21606433</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2013 Nov 18;8(11):e71915</RefSource>                <PMID Version="1">24260093</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am Soc Clin Oncol Educ Book. 2016;35:34-42</RefSource>                <PMID Version="1">27249684</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2010 Nov 11;363(20):1938-48</RefSource>                <PMID Version="1">21067385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2013 Feb;13(1):31-9</RefSource>                <PMID Version="1">23098574</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Dec 1;32(34):3840-7</RefSource>                <PMID Version="1">25349301</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2000 Aug 17;406(6797):747-52</RefSource>                <PMID Version="1">10963602</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2013 Jun;139(2):539-52</RefSource>                <PMID Version="1">23674192</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS Med. 2010 May 25;7(5):e1000279</RefSource>                <PMID Version="1">20520800</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Sep 29;6(29):26560-74</RefSource>                <PMID Version="1">26387133</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Res Int. 2015;2015:357485</RefSource>                <PMID Version="1">25695063</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2014 Jul;146(2):235-44</RefSource>                <PMID Version="1">24928527</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2010;15(5):466-75</RefSource>                <PMID Version="1">20427382</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2013 Sep;24(9):2298-304</RefSource>                <PMID Version="1">23704201</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Compr Canc Netw. 2016 Mar;14(3):324-54</RefSource>                <PMID Version="1">26957618</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 Aug;22(8):1736-47</RefSource>                <PMID Version="1">21709140</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Histopathology. 1991 Nov;19(5):403-10</RefSource>                <PMID Version="1">1757079</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2011 Aug 15;117(16):3658-69</RefSource>                <PMID Version="1">21387260</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2015 Aug;22(8):2475-82</RefSource>                <PMID Version="1">25805233</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2009 Jun 18;9:192</RefSource>                <PMID Version="1">19534825</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Surg. 2015 Jan 14;15:1</RefSource>                <PMID Version="1">25586679</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ecancermedicalscience. 2015 Mar 31;9:518</RefSource>                <PMID Version="1">25932042</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 May 20;25(15):2127-32</RefSource>                <PMID Version="1">17513820</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Assoc Med Bras (1992). 2012 Mar-Apr;58(2):178-87</RefSource>                <PMID Version="1">22569612</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2010;12(5):R68</RefSource>                <PMID Version="1">20813035</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2007 May 1;109(9):1721-8</RefSource>                <PMID Version="1">17387718</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Opin Obstet Gynecol. 2008 Feb;20(1):40-6</RefSource>                <PMID Version="1">18197004</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2016 Feb;27(2):249-56</RefSource>                <PMID Version="1">26598540</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2006 Jun 7;295(21):2492-502</RefSource>                <PMID Version="1">16757721</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">survival analysis</Keyword>            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>        </KeywordList>        <CoiStatement>Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30083066</ArticleId>            <ArticleId IdType="doi">10.1177/1179554918790563</ArticleId>            <ArticleId IdType="pii">10.1177_1179554918790563</ArticleId>            <ArticleId IdType="pmc">PMC6071162</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>